Abstract
Reaching a histologic diagnosis of prostatic cancer (CaP) is central to its treatment and outcome. Preoperative transrectal ultrasound (TRUS) guided biopsies miss 25-40% of higher grade CaP found in post prostatectomy specimen. MRI-US fusion biopsy technique is a technological advance with software based integration of prior MRI images and real time TRUS to improvise the prostatic biopsy yield. On combining systematic biopsies with targeted ones, along with MRI detected high risk CaP areas, 22% more low risk CaP were found. Hence, fusion biopsy leads to better detection of "clinically relevant" CaP. In certain groups of patients like elevated PSA with negative biopsies and those on active surveillance (AS), this fusion technique would make a difference in management.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
